لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Cerchietti LC; Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA.; Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA., Lopes EC; Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA., Yang SN; Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA., Hatzi K; Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA.; Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA., Bunting KL; Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA.; Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA., Tsikitas LA; Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA., Mallik A; Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA., Robles AI; Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Walling J; Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Varticovski L; Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Shaknovich R; Department of Pathology, Weill Cornell Medical College of Cornell University, New York, New York, USA., Bhalla KN; Medical College of Georgia Cancer Center, Augusta, Georgia, USA., Chiosis G; Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. chiosisg@mskcc.org., Melnick A; Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA. amm2014@med.cornell.edu.; Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA. amm2014@med.cornell.edu.

المصدر: Nature medicine [Nat Med] 2024 May; Vol. 30 (5), pp. 1503.

نوع المنشور: Published Erratum

بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Cerchietti LC; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Hatzi K; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Caldas-Lopes E; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Yang SN; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Figueroa ME; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Morin RD; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Hirst M; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Mendez L; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Shaknovich R; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Cole PA; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Bhalla K; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Gascoyne RD; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Marra M; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Chiosis G; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Melnick A; Hematology and Oncology Division, and Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Department of Pathology, Weill Cornell Medical College, New York, New York, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.

المصدر: The Journal of clinical investigation [J Clin Invest] 2010 Dec 01; Vol. 120 (12), pp. 4569-82. Date of Electronic Publication: 2010 Nov 01.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*pharmacology , DNA-Binding Proteins/*antagonists & inhibitors , E1A-Associated p300 Protein/*antagonists & inhibitors , Lymphoma, Large B-Cell, Diffuse/*drug therapy, Animals ; Cell Line, Tumor ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; E1A-Associated p300 Protein/genetics ; E1A-Associated p300 Protein/metabolism ; Female ; Histone Deacetylase Inhibitors/pharmacology ; Humans ; Lymphoma, Large B-Cell, Diffuse/metabolism ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Mice ; Mice, SCID ; Molecular Chaperones/genetics ; Molecular Chaperones/metabolism ; Proto-Oncogene Proteins c-bcl-6 ; Xenograft Model Antitumor Assays

المؤلفون: Navigante AH; Internal Medicine Department, Instituto Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina., Castro MA, Cerchietti LC

المصدر: Journal of pain and symptom management [J Pain Symptom Manage] 2010 May; Vol. 39 (5), pp. 820-30.

نوع المنشور: Comparative Study; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 8605836 Publication Model: Print Cited Medium: Internet ISSN: 1873-6513 (Electronic) Linking ISSN: 08853924 NLM ISO Abbreviation: J Pain Symptom Manage Subsets: MEDLINE

مواضيع طبية MeSH: Dyspnea/*drug therapy , Midazolam/*therapeutic use , Morphine/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Analgesics, Opioid/therapeutic use ; Anti-Anxiety Agents/therapeutic use ; Drug Administration Schedule ; Dyspnea/complications ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/complications ; Patient Selection ; Perception/drug effects ; Treatment Outcome

المؤلفون: Cerchietti LC; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA., Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH, Yang SN, Garcia M, Coop A, Mackerell AD Jr, Privé GG, Melnick A

المصدر: Cancer cell [Cancer Cell] 2010 Apr 13; Vol. 17 (4), pp. 400-11.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Large B-Cell, Diffuse/*pathology , Proto-Oncogene Proteins/*antagonists & inhibitors , Repressor Proteins/*antagonists & inhibitors, Animals ; Cell Division ; Cell Survival/drug effects ; Crystallography, X-Ray ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Mice ; Mice, Inbred C57BL ; Models, Molecular ; Protein Conformation ; Proto-Oncogene Proteins/chemistry ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/toxicity ; Repressor Proteins/chemistry ; Repressor Proteins/genetics ; Repressor Proteins/toxicity ; Transcription, Genetic ; Zinc Fingers

المؤلفون: Cerchietti LC; Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA., Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A

المصدر: Nature medicine [Nat Med] 2009 Dec; Vol. 15 (12), pp. 1369-76. Date of Electronic Publication: 2009 Nov 22.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

مواضيع طبية MeSH: DNA-Binding Proteins/*antagonists & inhibitors , HSP90 Heat-Shock Proteins/*antagonists & inhibitors , Lymphoma, B-Cell/*metabolism, DNA-Binding Proteins/metabolism ; Humans ; Lymphoma, B-Cell/pathology ; Protein Binding ; Proto-Oncogene Proteins c-bcl-6

المؤلفون: Cerchietti LC; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell College of Medicine, New York, NY 10065, USA, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A

المصدر: Blood [Blood] 2009 Apr 09; Vol. 113 (15), pp. 3397-405. Date of Electronic Publication: 2008 Oct 16.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , DNA-Binding Proteins/*antagonists & inhibitors , DNA-Binding Proteins/*pharmacology , Lymphoma, Large B-Cell, Diffuse/*drug therapy , Recombinant Proteins/*pharmacology , Repressor Proteins/*pharmacology, Animals ; Cell Death/drug effects ; Cell Division/drug effects ; Cell Line, Tumor ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Immune System/drug effects ; In Vitro Techniques ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Mice ; Mice, SCID ; Molecular Mimicry ; Nuclear Receptor Co-Repressor 2 ; Proto-Oncogene Proteins c-bcl-6 ; Recombinant Proteins/genetics ; Repressor Proteins/genetics ; Transcription, Genetic/drug effects ; Xenograft Model Antitumor Assays

المؤلفون: Cerchietti LC; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA., Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A

المصدر: Cancer research [Cancer Res] 2008 May 01; Vol. 68 (9), pp. 3361-9.

نوع المنشور: Evaluation Study; Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: DNA-Binding Proteins/*antagonists & inhibitors , Drug Delivery Systems/*methods , Lymphoma, Large B-Cell, Diffuse/*drug therapy , Peptides/*therapeutic use , Signal Transduction/*drug effects , Transcription Factors/*antagonists & inhibitors, Amino Acid Sequence ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Cell Death/drug effects ; Cell Line, Tumor ; Drug Synergism ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/metabolism ; Molecular Sequence Data ; Peptide Fragments/pharmacology ; Peptide Fragments/therapeutic use ; Peptides/pharmacology ; Proto-Oncogene Proteins c-bcl-6 ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Up-Regulation

المؤلفون: Cerchietti LC; Translational Research Unit, Angel H Roffo Cancer Institute, Universidad de Buenos Aires, Buenos Aires, Argentina. lcerchie@aecom.yu.edu, Navigante AH, Castro MA

المصدر: Nutrition and cancer [Nutr Cancer] 2007; Vol. 59 (1), pp. 14-20.

نوع المنشور: Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Routledge Country of Publication: United States NLM ID: 7905040 Publication Model: Print Cited Medium: Print ISSN: 0163-5581 (Print) Linking ISSN: 01635581 NLM ISO Abbreviation: Nutr Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cachexia/*drug therapy , Cyclooxygenase 2 Inhibitors/*therapeutic use , Fatty Acids, Omega-3/*therapeutic use , Fish Oils/*chemistry , Lung Neoplasms/*complications , Pyrazoles/*therapeutic use , Sulfonamides/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Appetite/drug effects ; C-Reactive Protein/analysis ; Celecoxib ; Cohort Studies ; Dietary Supplements ; Docosahexaenoic Acids/therapeutic use ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Eicosapentaenoic Acid/therapeutic use ; Fatigue/drug therapy ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Muscle Strength/drug effects ; Patient Compliance ; Syndrome ; Weight Gain/drug effects

المؤلفون: Cerchietti LC; Translational Research Unit, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina. lcerchietti@gmail.com, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, Cabalar ME, Roth B, Negretti G, Sheinker B, Uchima P

المصدر: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2006 Aug 01; Vol. 65 (5), pp. 1330-7. Date of Electronic Publication: 2006 Jun 09.

نوع المنشور: Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 7603616 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0360-3016 (Print) Linking ISSN: 03603016 NLM ISO Abbreviation: Int J Radiat Oncol Biol Phys Subsets: MEDLINE

مواضيع طبية MeSH: Dipeptides/*administration & dosage , Head and Neck Neoplasms/*drug therapy , Head and Neck Neoplasms/*radiotherapy , Stomatitis/*prevention & control, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin/adverse effects ; Double-Blind Method ; Fluorouracil/adverse effects ; Humans ; Injections, Intravenous ; Middle Aged ; Mouth Mucosa/drug effects ; Mouth Mucosa/radiation effects ; Stomatitis/etiology